EDITORIAL

Atrial fibrillation: an emerging epidemic?

J S Steinberg

Correspondence to:
Correspondence to:
Jonathan S Steinberg
MD, St Luke’s-Roosevelt Hospital Center, 1111 Amsterdam Avenue, New York, NY 10025, USA; jss7@columbia.edu

---

An aging general population, coupled with improved treatments for those individuals with coronary artery disease, hypertension, or heart failure, has led to a dramatic increase in the prevalence of atrial fibrillation

---

Keywords: atrial fibrillation

The first 150 words of the full text of this article appear below.

Atrial fibrillation (AF) is the most common arrhythmic condition facing physicians, afflicting almost 1 in 20 people over the age of 60.¹ The prevalence of AF is on the rise, due, in part, to an aging general population and to increased longevity resulting from improved medical care among patients with coronary artery disease, hypertension and heart failure—all chronic cardiac conditions which predispose to AF.^2,3 It is estimated that slightly less than 1% of the general population (well over two million in the USA) currently have AF, and the prevalence will increase 2.5-fold by the year 2050.¹ Prevalence figures for AF are underestimates because AF may be undiagnosed if sporadic and if not associated with significant symptoms.

AF is clinically important because it contributes to the incidence of heart failure, stroke, and both overall and cardiovascular mortality. The mechanism(s) by which AF contributes to increased mortality rate^2,4–6 is currently uncertain. Moreover, . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• McKenna, C, Palmer, S, Rodgers, M, Chambers, D, Hawkins, N, Golder, S, Van Hout, S, Pepper, C, Todd, D, Woolacott, N (2009). Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom. Heart 95: 542-549 [Abstract] [Full Text]  
• Comtois, P., Sakabe, M., Vigmond, E. J., Munoz, M., Texier, A., Shiroshita-Takeshita, A., Nattel, S. (2008). Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates. Am. J. Physiol. Heart Circ. Physiol. 295: H1489-H1504 [Abstract] [Full Text]  
• Voeller, R. K., Schuessler, R. B., Damiano, R. J. Jr. (2008). Surgical Treatment of Atrial Fibrillation. Card Surg Adult 3: 1375-1394 [Full Text]  
• Anderson, N., Fuller, R., Dudley, N. (2007). 'Rules of thumb' or reflective practice? Understanding senior physicians' decision-making about anti-thrombotic usage in atrial fibrillation. QJM 100: 263-269 [Abstract] [Full Text]  
• Cardin, S., Libby, E., Pelletier, P., Le Bouter, S., Shiroshita-Takeshita, A., Le Meur, N., Leger, J., Demolombe, S., Ponton, A., Glass, L., Nattel, S. (2007). Contrasting Gene Expression Profiles in Two Canine Models of Atrial Fibrillation. Circ. Res. 100: 425-433 [Abstract] [Full Text]  
• Steinberg, J. S. (2006). Desperately Seeking a Randomized Clinical Trial of Resynchronization Therapy for Patients With Heart Failure and Atrial Fibrillation. J Am Coll Cardiol 48: 744-746 [Full Text]  
• Miller, P. S.J., Drummond, M. F., Langkilde, L. K., McMurray, J. J.V., Ogren, M. (2005). Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 7: C41-C54 [Abstract] [Full Text]  
• Fuller, R, Dudley, N J (2005). Atrial fibrillation: will new drugs and patient choice improve anticoagulation outcomes?. Heart 91: 423-424 [Abstract] [Full Text]  
• Miller, P. S.J., Andersson, F. L., Kalra, L. (2005). Are Cost Benefits of Anticoagulation for Stroke Prevention in Atrial Fibrillation Underestimated?. Stroke 36: 360-366 [Abstract] [Full Text]  
• Halperin, J. L. (2005). Ximelagatran: Oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. J Am Coll Cardiol 45: 1-9 [Abstract] [Full Text]  
• Klein, A. L., Murray, R. D., Becker, E. R., Culler, S. D., Weintraub, W. S., Jasper, S. E., Lieber, E. A., Apperson-Hansen, C., Heerey, A. M., Grimm, R. A., ACUTE Investigators, (2004). Economic analysis of a transesophageal echocardiography-guided approach to cardioversion of patients with atrial fibrillation: The ACUTE economic data at eight weeks. J Am Coll Cardiol 43: 1217-1224 [Abstract] [Full Text]  

eLetters:

Read all eLetters

Age is the key factor

Ganesh Nallur Shivu

Online, 16 Mar 2004 [Full text]